Regulatory compliance – Page 33

Record retention failures during system operation – inspection evidence requirements

Addressing Record Retention Failures During System Operation: An Inspection-Ready Playbook In the pharma manufacturing landscape, record retention failures can lead to significant operational challenges, especially during inspections. These failures can…

Change impact not assessed during inspection readiness – risk-based validation alignment

Assessment of Change Impact During Inspection Readiness: A Comprehensive Playbook In a highly regulated environment, the challenge of effectively assessing change impacts during inspection readiness poses significant risks to pharmaceutical…

Hybrid paper-electronic workflows uncontrolled during compliance audit – 21 CFR Part 11 compliance gaps

Managing Compliance Gaps in Hybrid Paper-Electronic Workflows During an Audit In the evolving landscape of pharmaceutical manufacturing, hybrid paper-electronic workflows pose significant challenges, particularly during compliance audits. When these workflows…

Requalification overdue during inspection readiness – regulatory deficiency risk

Addressing Requalification Delays During Inspection Readiness to Mitigate Regulatory Risks In the pharmaceutical landscape, regulatory compliance is not just critical; it is a cornerstone of operational integrity. A common issue…

ERES controls not implemented during validation lifecycle – preventing repeat Part 11 findings

Addressing ERES Control Failures During the Validation Lifecycle to Avoid Part 11 Findings In today’s pharmaceutical landscape, the integrity of electronic records and electronic signatures (ERES) is paramount. Failing to…

Change impact not assessed during inspection readiness – preventing repeat validation findings

Addressing Unassessed Change Impact During Inspection Preparedness to Avoid Recurrence of Validation Issues In pharmaceutical manufacturing, unaddressed changes can lead to critical compliance infringements, particularly during inspections. Auditors from FDA,…

System access controls weak during inspection walkthrough – preventing repeat Part 11 findings

Enhancing System Access Controls to Avoid Part 11 Findings During Inspections The integrity of pharmaceutical manufacturing processes heavily relies on stringent system access controls, especially in the context of electronic…

CSV compliance weak during inspection readiness – inspection evidence expectations

Addressing Weak CSV Compliance During Inspection Readiness: Practical Strategies In the pharmaceutical industry, robust Computer System Validation (CSV) compliance is imperative for successful inspections by regulatory bodies such as the…

Hybrid paper-electronic workflows uncontrolled during system upgrade – inspection evidence requirements

Managing Uncontrolled Hybrid Paper-Electronic Workflows During System Upgrades During system upgrades, the integrity of hybrid paper-electronic workflows can often become compromised, leading to potential non-compliance and data integrity issues. In…

CSV compliance weak during lifecycle management – regulatory deficiency risk

Strengthening CSV Compliance Throughout the Lifecycle: Mitigating Regulatory Deficiency Risks In the pharmaceutical industry, compliance with Computerized System Validation (CSV) is crucial throughout the lifecycle of a system. Weak adherence…

System access controls weak during validation lifecycle – CAPA and revalidation strategy

Mitigating Weak System Access Controls During Validation Lifecycle: A CAPA Playbook In an era of heightened regulatory scrutiny, pharmaceutical companies are increasingly faced with challenges related to system access controls…

Change impact not assessed during change control – regulatory deficiency risk

Navigating Regulatory Risks: Assessing Change Impact During Change Control The pharmaceutical industry faces continuous scrutiny from regulatory bodies, emphasizing the importance of change control processes. A significant risk arises when…